ClinicalTrials.gg
RecruitingNCT07853768Updated Oct 15, 2026

Accuro XV Ultrasound Imaging System for BoneEnhance and Fracture Detection Algorithms

An interventional study of Accuro XV Ultrasound Imaging System in Fracture Arm, Fracture Leg and Wrist Injury, sponsored by Rivanna Medical, Inc.. Recruiting at 10 sites in United States. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Rivanna Medical, Inc. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Jan 2024, registered Jun 2026).
  • Started Jan 2024; still recruiting 2 years 9 months later.
Updated Oct 15, 2026Study contact changedNewly registered+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25,000
Allocation
Not applicable
Ages
5 Years and older
Sex
All
01

Study summary

The Accuro XV is a cart-based, bedside ultrasound instrument that incorporates new signal processing-based technologies for enhanced bone and soft-tissue imaging.

Patients presenting to the Study Setting (e.g., Emergency Departments, urgent care centers, orthopedic clinics, radiology departments, and other clinical environments with access to standard-of-care (SOC) imaging with a suspected distal extremity injury (wrist, forearm, ankle, or lower leg) who have undergone SOC imaging during their clinical evaluation, will be enrolled for additional extremity imaging with the Accuro XV.

In this feasibility study, investigators will assess the safety of Accuro XV by review of any adverse events (AEs) and by comparing the comfort level of patients during Accuro XV image capture and standard-of-care imaging. Investigators will retrospectively assess image quality by reviewing all images captured to ensure the image is clear of artifact and other visual imperfections. The de-identified imaging data will then be used for algorithm development and testing. This data will help to verify plans for future study protocols and help to ensure the device is optimized for its clinical use prior to further clinical studies. The results will also be used as an input to RIVANNA's usability and human factors engineering process per IEC 60601-1-6 as recognized by FDA.

The Accuro XV is investigational in this study and is not intended to guide clinical decision-making.

02

Conditions studied

  • Fracture Arm
  • Fracture Leg
  • Wrist Injury
  • Ankle Injury

Keywords

  • distal extremity fracture
  • bone fracture
  • musculoskeletal injury
  • extremity trauma
  • ultrasound imaging
  • point-of-care ultrasound
  • volumetric ultrasound
  • 3D ultrasound
  • bone imaging
  • soft tissue imaging
  • fracture detection
  • Accuro XV
  • Medical Device Feasibility
  • Image Quality
  • Algorithm Development
03

In context

Wrist Injuries

46 studies on the registry are indexed under Wrist Injuries; 11 are open to participants now.

This study's planned enrollment of 25,000 is above the median of 53 across 32 interventional studies indexed under Wrist Injuries.

Browse Wrist Injuries studies →

Lead sponsor

This is the only study on the registry with Rivanna Medical, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Sites are currently on two different protocol Revisions.

Inclusion criteria

Inclusion Criteria

  • Age greater than or equal to 5 years.
  • The patient is presenting for distal limb injury of the wrist, forearm, ankle, or lower leg.
  • The patient is scheduled to receive an X-ray that includes a view of the ankle, lower leg, wrist, and/or forearm or any patient that received an X-ray accessible by the study team for the studied anatomy in the past 48 hours.
  • English and/or Spanish speaking.

Exclusion criteria

Exclusion Criteria

  • An open fracture, grossly open wound, or severe angulation of the limb is present.
  • Patients for whom the site investigator feels that study participation could prohibit or impair ongoing medical care.
  • Known allergy to ultrasound couplants.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25,000 participants (estimated)

Study arms

  • Experimental
    Accuro XV Imaging

    Participants with a distal extremity injury who have undergone standard-of-care imaging will receive additional imaging with the Accuro XV ultrasound imaging system. Accuro XV imaging will be performed after completion of standard-of-care clinical imaging and will not be used for clinical decision-making or patient management. Imaging data collected during the study will be used to evaluate device feasibility, safety, image quality, and to support the development and testing of future algorithms.

    Device: Accuro XV Ultrasound Imaging System

Interventions

  • DeviceAccuro XV Ultrasound Imaging System

    The Accuro XV Ultrasound Imaging System is a cart-based ultrasound imaging device designed to acquire volumetric images of bone and soft tissue anatomy of the distal extremities. In this study, participants will undergo additional Accuro XV imaging following standard-of-care imaging for a distal extremity injury. The imaging procedure includes acquisition of multiple views of the injured anatomy using ultrasound technology and advanced image-processing methods to generate three-dimensional representations of bone and soft tissue structures. Images collected during the study will be used to evaluate device feasibility, safety, image quality, and to support the development and testing of future algorithms. Accuro XV imaging results will not be used for clinical decision-making.

06

What researchers measure

Primary outcomes

  1. Accuro XV Image Quality Assessment

    Retrospective assessment of acquired Accuro XV images for artifacts and other visual imperfections to evaluate image quality and suitability for subsequent analysis and algorithm development.

    Time frame: From Accuro XV image acquisition through completion of retrospective image-quality assessment, up to 48 months.

  2. Feasibility of Accuro XV Imaging Acquisition

    Successful acquisition of Accuro XV images of the target distal extremity anatomy according to study procedures; site PIs, AIs, and other Accuro XV users will be queried on how Accuro XV fits into their clinical workflow in terms of usability, maneuverablity, reliability and more. Surveys to be developed.

    Time frame: During and immediately after Accuro XV imaging on the day of enrollment.

  3. Participant Comfort During Imaging

    Participant-reported comfort and pain scores associated with Accuro XV imaging collected through the participant questionnaire. Participants completed a questionnaire assessing pain associated with both standard-of-care imaging and Accuro XV scanning. Specifically, participants were asked to rate their pain (1) before standard-of-care imaging, (2) during standard-of-care imaging, (3) before Accuro XV scans, and (4) during Accuro XV scans. Pain was measured using an 11-point Likert-type scale ranging from 0 ("none") to 10 ("severe"), with higher scores indicating greater pain.

    Time frame: Immediately after Accuro XV imaging on the day of enrollment.

Secondary outcomes

  1. Likert-Type Scale Participant-reported Imaging Modality Preference

    Participant-reported preference between Accuro XV imaging and standard-of-care imaging modalities. Participants completed a questionnaire assessing satisfaction with both standard-of-care imaging and Accuro XV scanning. Participants were asked to rate their satisfaction with each imaging modality on an 11-point Likert-type scale ranging from 0 ("not satisfied at all") to 10 ("very satisfied"), with higher scores indicating greater satisfaction. In addition, participants were asked to indicate their preferred imaging modality by selecting either Accuro XV, standard-of-care imaging, or no preference.

    Time frame: Immediately after Accuro XV imaging on the day of enrollment.

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Aug 2027, 43 months after the start.

Of 18 interventional studies with no phase under Wrist Injuries, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 58. This study's planned 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Oct 2, 2026
StartActual
Jan 29, 2024
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • Rush University Medical Center · Chicago, United States
  • Thomas Jefferson University Hospital · Philadelphia, United States
Oct 13, 2026
Contact
Study contact changed: p•••@rivannamedical.com · •••0589→d•••@rivannamedical.com · •••0589. See the current contact
Oct 15, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Texas Tech University Health Sciences Center · El Paso, United StatesContact person changed (no phone or email listed)
Oct 13, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 4 updates
  1. Oct 15, 2026
    Contact Study contact changed: p•••@rivannamedical.com · •••0589→d•••@rivannamedical.com · •••0589. See the current contact
  2. Oct 13, 2026
    2 sites added
    Show 2 added (2 United States)
    • Rush University Medical Center · Chicago, United States
    • Thomas Jefferson University Hospital · Philadelphia, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Texas Tech University Health Sciences Center · El Paso, United StatesContact person changed (no phone or email listed)
  3. Oct 6, 2026
    Minor edits only
    + 2 other changes: verification date and description
  4. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853768
Lead sponsor
Rivanna Medical, Inc.
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Jan 29, 2024
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Delphine Le Roux, PhD
Contact
dleroux@rivannamedical.com
804-514-0589

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion